{
    "clinical_study": {
        "@rank": "72024", 
        "acronym": "REPEAT", 
        "arm_group": [
            {
                "arm_group_label": "Single intracoronary cell application", 
                "arm_group_type": "Active Comparator", 
                "description": "Single intracoronary application of autologous bone marrow derived mononuclear cells"
            }, 
            {
                "arm_group_label": "repeated (2 times) intracoronary cell application", 
                "arm_group_type": "Active Comparator", 
                "description": "2 times (interval 4 months) intracoronary application of autologous bone marrow derived mononuclear cells"
            }
        ], 
        "brief_summary": {
            "textblock": "Single or repeated application of autologous bone marrow-derived stem cells to treat chronic\n      post-infarction heart failure"
        }, 
        "brief_title": "Compare the Effects of Single Versus Repeated Intracoronary Application of Autologous Bone Marrow-derived Mononuclear Cells on Mortality in Patients With Chronic Post-infarction Heart Failure", 
        "completion_date": {
            "#text": "January 2019", 
            "@type": "Anticipated"
        }, 
        "condition": "Heart Failure", 
        "condition_browse": {
            "mesh_term": [
                "Heart Failure", 
                "Infarction"
            ]
        }, 
        "detailed_description": {
            "textblock": "Improve mortality and morbidity in patients with symptomatic chronic post-infarction heart\n      failure under full dose conventional medical and device treatment including\n      resynchronization therapy, by single versus repeated intracoronary infusion of autologous\n      bone marrow-derived mononuclear cells."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Previous myocardial infarction at least 3 months ago, open infarct vessel or bypass\n\n          -  Left ventricular ejection fraction (LVEF) \u2264 45% on echocardiography\n\n          -  Stable chronic heart failure NYHA class II to III under constant (4 weeks)\n             evidence-based optimal medical treatment\n\n          -  age 18 - 80 years\n\n          -  written informed consent\n\n          -  women of childbearing age: negative pregnancy test; effective contraception for the\n             first 8 months in the trial\n\n        Exclusion Criteria:\n\n          -  Non-ischemic cardiomyopathy\n\n          -  Necessity for revascularization in other vessel than the infarct vessel at the time\n             of study therapy\n\n          -  Hemodynamic relevant severe valvular disease with indication for operative /\n             interventional revision\n\n          -  Heart failure with preserved ejection fraction (diastolic heart failure), LVEF > 45%\n\n          -  Unstable Angina\n\n          -  Severe peripheral artery occlusive disease (\u2265 Fontaine stadium III)\n\n          -  Active infection (C-reactive protein > 10 mg/dl), chronic active hepatitis; any\n             chronic inflammatory disease, HIV infection\n\n          -  Neoplastic disease without documented remission in the last 5 years\n\n          -  Stroke \u2264 3 months\n\n          -  Impaired renal function (Serum creatinine > 2,5 mg/dl) at the time of study inclusion\n\n          -  Relevant liver disease (GOT > 2x upper normal limit, spontaneous INR > 1,5).\n\n          -  Diseases of hematopoetic system, anemia (Hemoglobin < 8.5 mg/dl), thrombocytopenia <\n             100.000/\u00b5l)\n\n          -  Splenomegaly\n\n          -  Allergy or intolerance of clopidogrel, prasugrel, ticagrelor, heparin, bivalirudin\n\n          -  History of bleeding disorder\n\n          -  gastrointestinal bleeding \u2264 3 months\n\n          -  major surgery or trauma \u2264 3 months\n\n          -  Uncontrolled hypertension\n\n          -  Pregnancy, lactation period\n\n          -  mental retardation\n\n          -  previous cardiac cell therapy within last 12 months\n\n          -  Participation in another clinical trial \u2264 30 days"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "80 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "676", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "September 19, 2012", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01693042", 
            "org_study_id": "2011-01-01REPEAT", 
            "secondary_id": "2011-000595-33"
        }, 
        "intervention": {
            "arm_group_label": [
                "Single intracoronary cell application", 
                "repeated (2 times) intracoronary cell application"
            ], 
            "description": "Intracoronary infusion into open vessel / bypass supplying previous (> 3 months) infarct area", 
            "intervention_name": "intracoronary infusion of autologous bone marrow-derived cells", 
            "intervention_type": "Biological", 
            "other_name": "t2c001"
        }, 
        "is_fda_regulated": "No", 
        "keyword": [
            "heart failure", 
            "old myocardial infarction", 
            "bone marrow-derived mononuclear cells", 
            "chronic", 
            "ischemic"
        ], 
        "lastchanged_date": "November 14, 2013", 
        "location": [
            {
                "contact": {
                    "email": "zeiher@em.uni-frankfurt.de", 
                    "last_name": "Andreas M Zeiher, MD", 
                    "phone": "+49 69 6301", 
                    "phone_ext": "5789"
                }, 
                "contact_backup": {
                    "email": "b.assmus@em.uni-frankfurt.de", 
                    "last_name": "Birgit Assmus, MD", 
                    "phone": "+49 69 6301", 
                    "phone_ext": "7387"
                }, 
                "facility": {
                    "address": {
                        "city": "Frankfurt", 
                        "country": "Germany", 
                        "zip": "60590"
                    }, 
                    "name": "Goethe University Frankfurt"
                }, 
                "investigator": [
                    {
                        "last_name": "Birgit Assmus, MD", 
                        "role": "Sub-Investigator"
                    }, 
                    {
                        "last_name": "Andreas M Zeiher, MD", 
                        "role": "Principal Investigator"
                    }
                ], 
                "status": "Not yet recruiting"
            }, 
            {
                "contact": {
                    "email": "b.assmus@em.uni-frankfurt.de", 
                    "last_name": "Birgit Assmus, MD", 
                    "phone": "+49 69 6301", 
                    "phone_ext": "7387"
                }, 
                "facility": {
                    "address": {
                        "city": "Frankfurt", 
                        "country": "Germany", 
                        "zip": "60590"
                    }, 
                    "name": "Goethe University; Cardiology"
                }, 
                "investigator": [
                    {
                        "last_name": "Andreas M Zeiher, MD", 
                        "role": "Principal Investigator"
                    }, 
                    {
                        "last_name": "Birgit Assmus, MD", 
                        "role": "Sub-Investigator"
                    }
                ], 
                "status": "Recruiting"
            }
        ], 
        "location_countries": {
            "country": "Germany"
        }, 
        "number_of_arms": "2", 
        "official_title": "Randomized Controlled Trial to Compare the Effects of Single Versus Repeated Intracoronary Application of Autologous Bone Marrow-derived Mononuclear Cells on Total and SHFM-predicted Mortality in Patients With Chronic Post-infarction Heart Failure", 
        "overall_contact": {
            "email": "zeiher@em.uni-frankfurt.de", 
            "last_name": "Andreas M Zeiher, MD", 
            "phone": "+49 69 6301", 
            "phone_ext": "5789"
        }, 
        "overall_contact_backup": {
            "email": "b.assmus@em.uni-frankfurt.de", 
            "last_name": "Birgit Assmus, MD", 
            "phone": "+49 69 6301", 
            "phone_ext": "7387"
        }, 
        "overall_official": [
            {
                "affiliation": "Cardiology, Goethe University Frankfurt", 
                "last_name": "Andreas M Zeiher, MD", 
                "role": "Principal Investigator"
            }, 
            {
                "affiliation": "Cardiology, Goethe University Frankfurt", 
                "last_name": "Birgit Assmus, MD", 
                "role": "Study Director"
            }
        ], 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "Germany: Paul-Ehrlich-Institut", 
            "has_dmc": "Yes"
        }, 
        "phase": "Phase 2/Phase 3", 
        "primary_completion_date": {
            "#text": "November 2018", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "2-year observed mortality is significantly lower in patients receiving 2 repeated intracoronary applications of autologous bone marrow-derived cells (t2c001) compared to patients receiving 1 intracoronary application of autologous bone marrow-derived cells (t2c001)", 
            "measure": "Mortality at 2 years after inclusion into the study", 
            "safety_issue": "No", 
            "time_frame": "2 years"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01693042"
        }, 
        "responsible_party": {
            "investigator_affiliation": "Johann Wolfgang Goethe University Hospitals", 
            "investigator_full_name": "A. M. Zeiher", 
            "investigator_title": "Prof. Dr. Andreas M. Zeiher", 
            "responsible_party_type": "Principal Investigator"
        }, 
        "secondary_outcome": {
            "description": "Efficacy endpoints:\nComparison between the 2 treatment groups at 2-year and 5-year follow-up\nCardiac mortality, cardiovascular mortality\nRehospitalisation for heart failure\nIschemic cardiac events (STEMI, NSTEMI, ACS)\nCoronary revascularisations (PCI / CABG)\nHeart transplantation, Assist-device implantation\nNew resynchronization therapy, ICD implantation\nNYHA-Status, NT-proBNP serum levels\nMinnesota Living with Heart Failure Questionnaire\nSafety endpoints:\nbleeding events, all in-hospital events (during hospitalization for BMC therapy), life-threatening arrhythmias, new malignancies", 
            "measure": "Morbidity at 2 and 5 years after inclusion into the study", 
            "safety_issue": "Yes", 
            "time_frame": "2 years and 5 years"
        }, 
        "source": "Johann Wolfgang Goethe University Hospitals", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Johann Wolfgang Goethe University Hospitals", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "November 2013", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "November 2013"
    }
}